STOCK TITAN

Longeveron Inc - LGVN STOCK NEWS

Welcome to our dedicated news page for Longeveron (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longeveron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longeveron's position in the market.

Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) will report its third quarter 2023 financial results on November 10, 2023. The company will host a conference call and webcast to discuss the results and provide updates on its clinical programs and corporate activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
conferences earnings
-
Rhea-AI Summary
Longeveron Inc. announces positive top-line results from its Phase 2a trial of Lomecel-B™ for the treatment of mild Alzheimer’s disease. The trial met its primary safety endpoint and showed encouraging efficacy observations. Additional biomarker data from the trial will be announced later this month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
clinical trial
-
Rhea-AI Summary
Longeveron Inc. closes registered direct offering, raising approximately $4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Summary
Longeveron Inc. announces a registered direct offering of 2,424,243 shares of common stock at $1.65 per share, expected to close on October 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
offering
-
Rhea-AI Summary
Longeveron announces positive results from Phase 2a trial of Lomecel-B™ for the treatment of mild Alzheimer’s disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.73%
Tags
clinical trial
-
News
Rhea-AI Summary
Longeveron Inc. provides a business update on their lead investigational product Lomecel-B™ and progress in clinical trials for various indications. Phase 2 ELPIS II trial in HLHS has exceeded enrollment threshold, Phase 2a CLEAR MIND trial in Alzheimer's disease on track to report results in October 2023, and Phase 2 trial for Aging-related Frailty ongoing in Japan. New long-term survival data shows positive outcomes. Company has strengthened its Board and executive leadership team. $30 million Rights Offering initiated to fund clinical development. Positive outlook for Lomecel-B™ and potential long-term shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Summary
Longeveron Inc. announces abstract acceptance for presentation at AHA meeting on long-term survival data from ELPIS 1 trial of Lomecel-B for HLHS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary
Longeveron Inc. to participate in H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Summary
Longeveron Inc. to participate in National Investment Banking Association conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences
Rhea-AI Summary
Longeveron Inc. announces the start of its rights offering with a subscription price of $3.00 per share. The subscription period ends on September 21, 2023. Longeveron reserves the right to modify or cancel the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.2%
Tags
none
Longeveron Inc

Nasdaq:LGVN

LGVN Rankings

LGVN Stock Data

8.17M
144.50k
11.49%
24.44%
0.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miami

About LGVN

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome